GSA Capital Partners’s Heron Therapeutics HRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding HRTX
GSA Capital Partners's HRTX Position: Q3 2026 in Review
GSA Capital Partners increased its Heron Therapeutics (HRTX) stake by 425% in Q3 2026, buying an estimated $1.68M and bringing the position to 5,473,797 shares worth $1.72M. The position accounts for 0.1% of the portfolio, ranked #246.
GSA Capital Partners first reported a position in HRTX in Q4 2019 and has held it in 22 quarters since. 159 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.
- GSA Capital Partners held 5,473,797 shares of Heron Therapeutics worth $1.72M as of Q3 2026.
- GSA Capital Partners bought 4,430,905 Heron Therapeutics shares in Q3 2026, an estimated $1.68M.
- Heron Therapeutics made up 0.1% of GSA Capital Partners's portfolio in Q3 2026, its #246 holding.
- GSA Capital Partners first reported a position in Heron Therapeutics in Q4 2019 and has held it in 22 quarters since.
- 159 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.
Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.